Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors(2024)

Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao on behalf of the Steering Committee the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of Chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of Chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of China Anti-Cancer Association(CACA) Chinese Society of Hematology of Chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association(SMEA)

中国癌症研究(英文版)2024，Vol.36Issue(3) ：240-256.DOI:10.21147/j.issn.1000-9604.2024.03.02

来源：

NETL
NSTL
万方数据

Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors(2024)

Zaiwei Song ¹Dan Jiang ²Lingling Yu ¹Yixuan Chen ²Daobin Zhou ³Yue Li ⁴Depei Wu ⁵Lingli Zhang ⁶Liyan Miao ⁷Jun Ma ⁸Jun Zhu ⁹Hongmei Jing ¹⁰Rongsheng Zhao ¹on behalf of the Steering Committee the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of Chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of Chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of China Anti-Cancer Association(CACA) Chinese Society of Hematology of Chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association(SMEA)

扫码查看

作者信息

1. Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing 100191,China;Therapeutic Drug Monitoring and Clinical Toxicology Center,Peking University,Beijing 100191,China
2. Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing 100191,China;Therapeutic Drug Monitoring and Clinical Toxicology Center,Peking University,Beijing 100191,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China
3. Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100005,China
4. Department of Cardiology,the First Affiliated Hospital,Harbin Medical University,Harbin 150001,China
5. Department of Hematology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China
6. Department of Pharmacy,Evidence-based Pharmacy Center,West China Second Hospital,Sichuan University,Chengdu 610041,China
7. Department of Pharmacy,the First Affiliated Hospital of Soochow University,Suzhou 215006,China
8. Department of Hematology and Oncology,Harbin Institute of Hematology and Oncology,Harbin 150010,China
9. Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Lymphoma,Peking University Cancer Hospital & Institute,Beijing 100142,China
10. Department of Hematology,Peking University Third Hospital,Beijing 100191,China
折叠

Abstract

Bruton's tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell lymphomas.However,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidence-based medicine.This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method.The Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,respectively.This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special populations.This multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

Key words

Consensus/BTK inhibitors/safety/adverse drug events/drug-drug interactions

引用本文复制引用

基金项目

National Natural Science Foundation of China(NSFC)(72074005)

National Natural Science Foundation of China(NSFC)(72304007)

special fund of the National Clinical Key Specialty Construction Program,P.R.China(2023)()

出版年

2024

中国癌症研究(英文版)

中国抗癌协会北京市肿瘤研究所

中国癌症研究(英文版)

CSTPCDCSCD

影响因子：1.592

ISSN：1000-9604

参考文献量2

段落导航